Follow-on Biologics Savings Lower In Administration Budget Proposal
Executive Summary
The Obama administration has cut by about one-third its estimate of the fiscal benefit expected to accrue to the treasury from an approval pathway for follow-on biologics
You may also be interested in...
Follow-On Biologics Legislation Faces Tough Road Ahead; Momentum Stalled
Prospects for enactment of follow-on biologics legislation appear limited in the near term, according to Capitol Hill players in the debate
Follow The Follow-On Money: Obama’s Budget Has Modest Biogeneric Savings
The fiscal 2010 federal budget outlined by the Obama administration Feb. 25 takes a conservative view of the fiscal benefit of generic biologics - estimating they will contribute $9.2 billion over 10 years to help pay for health care reform
Follow-On Biologics Coding Tweaks Could Raise Savings By 30% – CBO
Giving a follow-on biologic the same reimbursement code as its brand name counterpart would increase the savings from FOBs by 30 percent for the federal government's mandatory health care programs, the Congressional Budget Office estimates